Recommended Ceftazidime-Avibactam Dosing for Serum Creatinine 3 mg/dL
For a patient with serum creatinine of 3 mg/dL, administer ceftazidime-avibactam 1.25 g (1000 mg ceftazidime/250 mg avibactam) IV every 24 hours, infused over 2-3 hours.
Dosing Rationale
A serum creatinine of 3 mg/dL indicates moderate-to-severe renal impairment requiring dose adjustment. Using the Cockcroft-Gault equation to estimate creatinine clearance (CrCL), this typically corresponds to a CrCL of approximately 15-30 mL/min, depending on the patient's age, weight, and sex 1.
FDA-Approved Renal Dosing Algorithm
The FDA label provides clear guidance for renal dose adjustment 1:
- CrCL 30-16 mL/min: 1 gram every 24 hours
- CrCL 15-6 mL/min: 500 mg every 24 hours
- CrCL <5 mL/min: 500 mg every 48 hours
Calculate the patient's estimated CrCL using Cockcroft-Gault 1:
- Males: CrCL (mL/min) = [Weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)]
- Females: 0.85 × male value
Critical Considerations for Optimal Dosing
Extended infusion is essential for optimal outcomes. Recent guideline evidence demonstrates that 3-hour infusions of ceftazidime-avibactam are independently associated with improved 30-day survival in patients with carbapenem-resistant infections 2. This is particularly important given that renal impairment already reduces drug clearance.
Beware of underdosing in renal impairment. A critical 2024 study found that renal-adjusted doses of ceftazidime-avibactam were independently associated with higher mortality (HR 4.47,95% CI 1.09-18.03) in patients with KPC-producing Klebsiella pneumoniae bloodstream infections 3. The median dose in that study was only 1.9 g daily, which may have provided inadequate drug exposure.
Pharmacokinetic Considerations
Ceftazidime-avibactam is eliminated almost exclusively by glomerular filtration 1. In renal impairment:
- Clearance is dramatically reduced: Studies show clearance drops from ~6 L/h in normal function to ~2.5 L/h in severe renal impairment 4, 5
- Half-life is prolonged: From ~2 hours to 4-5 hours or longer 6, 5
- Volume of distribution remains relatively stable at 17-35 L for ceftazidime 4, 5
Monitoring and Adjustment Strategy
Start with 1 gram every 24 hours as the base dose for CrCL 15-30 mL/min 1
Consider increasing to 1.25 g every 24 hours for severe infections (bloodstream infections, pneumonia, intra-abdominal infections) to ensure adequate exposure, given the mortality risk associated with underdosing 3
Infuse over 2-3 hours rather than the standard 2 hours to optimize pharmacodynamic target attainment 2, 7
Reassess renal function regularly: If CrCL improves above 30 mL/min, increase to 1.25 g every 12 hours; if it worsens below 15 mL/min, reduce to 500 mg every 24 hours 1
Common Pitfalls to Avoid
Do not use standard dosing (2.5 g every 8 hours) without dose adjustment—this risks drug accumulation and potential neurotoxicity, as plasma concentrations can exceed 104 mg/L 8
Do not reflexively reduce doses too aggressively—the mortality signal associated with renal-adjusted dosing suggests that current FDA recommendations may be conservative for severe infections 3
Do not use short infusions—standard 30-minute infusions are suboptimal; extended 2-3 hour infusions improve PK/PD target attainment 2, 7
If the patient requires hemodialysis, give a loading dose of 1 gram, then 1 gram after each dialysis session 1